The newly approved prefilled syringe for self-injection of Vyvgart Hytrulo will provide more convenience and flexibility for ...

Dr Nicholas Silvestri reports that the 2025 AAN meeting highlighted significant advances in myasthenia gravis, including improved diagnostics and emerging therapies.

The U.S. Food and Drug Administration has approved a self-injection version of Vyvgart Hytrulo (efgartigimod alfa and ...

The researchers believe future myasthenia gravis treatments could target specific antibody interactions rather than relying on more general immunosuppression treatments. "This study not only ...

By mapping antibody binding sites on the receptor, we revealed a surprising diversity in how autoantibodies contribute to myasthenia gravis. This knowledge helps explain why some patients respond ...

Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be ...

Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized myasthenia gravis ...

Ryan Hibbs, study's senior author, Neurobiology Professor The researchers believe future myasthenia gravis treatments could target specific antibody interactions rather than relying on more ...

The first risk to consider would be in terms of development of its lead autologous CD-19 CAR-T KYV-101 for the treatment of patients with Myasthenia Gravis in the ongoing phase 2 KYSA-6 study.

Chinese biotech RemeGen (SHA: 688331) has reported positive late-stage clinical trial data for its dual-target fusion protein ...

US biotech Cartesian Therapeutics has reported that patients with generalized myasthenia gravis (gMG) continued to experience ...